

澳大利亚生物技术协会 澳大利亚医疗技术公司名录



公司介绍

公司名称: PolyNovo 有限责任公司

主要联系人姓名: Paul Brennan

主要联系人职务: 首席执行官

公司网址: www.polyново.com

公司地址: 2/320 Lorimer St Port Melbourne VIC 3207

公司已经上市:

公司简介

PolyNovo 采用专利生物降解聚合技术 NovoSorb™, 为整形外科手术和组织修复研制再生性装置。

NovoSorb™ 是指一类医用级聚合物, 由其组成的医疗装置可以帮助重建或修复坏死组织。

NovoSorb™ 可根据需求, 调整强度、弹性和降解性。

NovoSorb™ 在安全性, 毒理学特性和强度上都具有明显的优势。

PolyNovo 将通过和目标领域内的龙头企业建立战略合作伙伴关系, 进入市场。

PolyNovo 生产的一种生物降解暂时基质(BTM)在对游离皮瓣供区和三名重度烧伤病人的治疗中表现出极佳的治疗效果。治疗后的皮肤少有痉挛, 恢复极好, 皮肤有弹性, 达到了最佳的美容效果。我们目前正在着手建立 CE 标记的临床测试, 与此同时, 我们也已经向 FDA 提交了应用于手术伤口的 510(K)申请 (目前仍在等待批复)。

本公司 NovoSorb™ 伤口创面已获得 CE 标记和 510K 批准, 用于负压伤口治疗。我们目前正在该领域寻求战略合作伙伴。

PolyNovo 拥有 TUV SUD 和 ISO13485 认证。

关键技术或领先技术

公司独特的聚合物技术可以针对多种装置应用，设计出不同的模量和弹性特质。我们在可降解和洗脱聚合物应用领域拥有专利。该技术具有可生物降解、低毒性，且针对多种再生性装置具有可塑性，我们对公司的未来充满希望。

类别

装置

整形外科

泌尿科和妇科

伤口护理

该技术有可能在疝气修补，乳房重塑或其他再生性应用

关键技术或领先技术的发展阶段

临床试验中阶段

已经获得注册- NovoPore

合作机会

PolyNovo 战略规划清晰，在我们熟悉的医疗设备领域内寻求战略合作伙伴。欢迎各类基于本公司专利聚合物技术的合作，愿与您共同开发相关产品。我们在澳洲股票交易所的代号是 PNV。

Directory of Australian medtech companies



COMPANY DETAILS

Company name: PolyNovo Limited

Key contact name: Paul Brennan

Job title of key contact: CEO

Company website address: www.polynovo.com

Company address: 2/320 Lorimer St Port Melbourne VIC 3207

The company is Listed.

ABOUT THE COMPANY

PolyNovo develops regenerative devices for reconstructive surgery and tissue repair with our patented biodegradable polymer technology, NovoSorb™.

NovoSorb™ is a family of medical grade polymers used to form medical devices to reconstruct or repair failed tissue. NovoSorb™ can be tailored to a desired strength, elasticity or degradation profile.

NovoSorb™ has significant advantages in terms of *safety, toxicology profile* and *strength*.

PolyNovo will access the market through strategic partnerships with leaders in targeted segments.

PolyNovo manufactures a Biodegradable Temporising Matrix (BTM) which has been used in Free Flap donor sites and 3 full thickness burns patients with outstanding results. The quality of the healed skin is excellent with minimal skin contracture, high elasticity and excellent cosmetic outcomes. We are currently establishing CE Mark clinical trials and have a 510(k) filing with the FDA for Surgical Wounds (awaiting outcome of 510(k) process).

Our NovoSorb™ wound interface has both CE Mark and 510K approval for use in Negative Pressure Wound Therapy and we are looking at strategic partners in this space.

PolyNovo has TUV SUD accreditation and ISO13485

KEY OR LEAD TECHNOLOGY

Our unique Polymer technology allows us to design various modulus and elasticity characteristics for applications in a wide range of device technologies. We hold patents on biodegradable and eluting polymer applications. With the combination of biodegradability, low toxicity profile and the ability to tailor to various regenerative devices we see a bright future for PolyNovo.

Category

Devices:

Orthopaedics

Urology and gynaecology

Wound care

Potential in hernia repair, breast reconstruction and other regenerative applications.

Point of development of key or lead technology

In clinical trials –BTM

Has achieved registration – NovoPore

OPPORTUNITIES SOUGHT

PolyNovo has a clear regulatory strategy. We look for strategic business partners who innovate within our Medical Device Segments. We are open to collaborative development of products based on our Patented Polymer Technologies. Our ASX code is PNV.